Day 2 Program

Poster Session 2

Day 2: December 9, 2026

5:00 PM–6:30 PM CST

Exhibit Hall

Session Details

P2-1-01

EXAct‑DNA‑005 Complete: Prospective registry of tumor‑informed ctDNA MRD testing, treatment decisions, and outcomes in early breast cancer

Christy Russell, Abbott, Madison, WI

P2-1-02

Phase III PLANET trial of capecitabine / olaparib with or without pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after neoadjuvant chemotherapy plus pembrolizumab (BOOG 2025-03)

Robin van den Borg, Netherlands Cancer Institute, Amsterdam, Netherlands

P2-1-03

The REPOWER US mixed-methods study: a real-world study of patient experience, adherence, and quality of life during adjuvant cyclin-dependent kinase 4/6 (CDK4/6) inhibitor therapy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) early breast cancer

Maryam Lustberg, Yale School of Medicine, New Haven, CT

P2-1-04

Circulating tumor DNA-guided clinical decision-making across the breast cancer continuum- an emerging framework for treatment optimization

Nick Turner, Institute of Cancer Research, London, United Kingdom

P2-1-05

Tbcrc 058: a randomized phase 2 study of enzalutamide, enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (nct06099769)

Rita Nanda, University of Chicago Medicine, Chicago, IL

P2-1-06

Optimization of adjuvant systemic therapy in patients with early HER2+ or triple negative breast cancer who experience a pathological complete response after neoadjuvant systemic therapy and do not have molecular residual disease: a Phase II clinical trial (The MolecularPCR study) (Clinical trial in progress)

Carlos H. Barcenas, University of Texas MD Anderson Cancer Center, Houston, TX

P2-1-07

Serma (eubreast 5, ago-b-068): beyond the fluid—decoding the immunobiology of post-mastectomy seroma in an international prospective cohort study (nct05899387)

Nina Ditsch, University Augsburg, Augsburg, Germany

P2-1-08

ReDiscover-2, a phase 3 study of zovegalisib + fulvestrant versus capivasertib + fulvestrant as treatment for locally advanced or metastatic PIK3CA-mutant HR+/ HER2- breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor

Hope S Rugo, City of Hope Comprehensive Cancer Center, Duarte, CA

P2-1-09

A phase 1 open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of the KAT6 inhibitor, KC1086, in patients with advanced solid tumors, including estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer: preliminary safety and efficacy results

Binghe Xu, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

P2-1-10

Trial in Progress: A Phase 1, Open-Label, Dose-Escalation Study of a Personalized Vaccine Immunotherapy as a Single Agent and In Combination with Checkpoint Inhibitor for Triple Negative Breast Cancer

Keerthi Gogineni, Emory School of Medicine, Winship Cancer Institute, Atlanta, GA

P2-1-11

Pharmacokinetic and correlative assays from a Phase I/II study of Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients

Coy Heldermon, University of Florida, Gainesville, FL

P2-1-12

First-in-human evaluation of the deciparticle™-enabled mtor inhibitor sapu003: safety and preliminary activity

Cynthia Lee, Sapu Nano (US) LLC, San Diego, CA

P2-1-13

Alter (nct07151586): a phase ii randomized trial investigating upfront adc alternation in her2-low metastatic triple-negative breast cancer

Alexandre de Nonneville, Institut Paoli-Calmettes, Marseille, France

P2-1-14

Enabling shared decision making for adults with metastatic breast cancer: The Communicating Options for Advanced breast cancer Support and Treatment (COAST) Study

Shoshana M Rosenberg, Weill Cornell Medicine, New York, NY

P2-1-15

Caloric restriction for excess weight reduction and healthy weight maintenance during neoadjuvant systemic therapy for early breast cancer: The CREWE feasibility randomised controlled trial.

Emma Crewe, University of Oxford, Oxford, United Kingdom

P2-1-16

Recast: a randomized phase ii platform trial evaluating novel endocrine therapies to facilitate and safely select patients with hormone receptor-positive ductal carcinoma in situ for active surveillance

Jordan Jackson, University of California, San Francisco, San Francisco, CA

P2-1-17

A phase II, two-arm, randomized trial of immunogenicity of a multi-antigen, multi-epitope Th1 selective vaccine (STEMVAC) in triple-negative breast cancer

Julia Knight-Shefner, University of Wisconsin, Madison, WI

P2-1-18

Molecular MRI as a Noninvasive Method for the Detection of Lymph Node Involvement in Subjects with HER2 positive Breast Cancer: A Clinical Update

Koushik Govindarajan, Imagion Biosystems, Incline Village, CA

P2-1-19

A Randomized Phase 3 Trial of Intraoperative SRG-514 at the Tumor Resection Site in Patients Undergoing Breast-Conserving Surgery for Triple-Negative Breast Cancer (SRG-514-02)

Charles Carignan, SURGE Therapeutics, Cambridge, MA

P2-1-20

Post-market evaluation ofpegulicianine fluorescence guided surgery (pFGS): the Intraoperative Margin Performance and Clinical Utility (IMPACT) registry

Kate P. Smith, Lumicell, Inc, Waltham, MA

P2-1-21

Signal-er-101: a prospective trial of ctdna-guided cdk4/​6 inhibitor therapy in intermediate-risk er+/her2- early breast cancer

Reshma Mahtani, Baptist Health Wertheim Cancer Institute, Plantation, FL

P2-1-22

Post-market evaluation of the incidence of anaphylaxis and hypersensitivity reactions associated with pegulicianine administration during fluorescence-guided lumpectomy

Kate Smith, Lumicell, Inc, Waltham, MA

P2-1-23

Effect of acupuncture on appetite in patients with breast cancer receiving systemic therapy.

Salome Khutsurauli, Hillel Yaffe, Hadera, Israel

P2-1-24

Abcsg 61 / teodor: neoadjuvant treatment optimization driven by circulating tumor dna and endocrine responsiveness (nct07084558)

Daniel Egle, Tirol Kliniken / Innsbruck Medical University and Austrian Breast and Colorectal Cancer Study Group, Innsbruck, Austria

P2-1-25

Small: open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancer – a uk phase iii randomised multi-centre trial

Stuart A McIntosh, Queen's University Belfast, Belfast, United Kingdom

P2-1-27

CBCRC-01: A prospective evaluation of the gut microbiome and a pilot dietary intervention in patients with HR-positive/HER2-negative breast cancer receiving abemaciclib (GEMMA)

Maeve A. Hennessy, University of Chicago Medicine, Chicago, IL

P2-1-28

A First in Human Phase 1 Study of Intrathecal Peptide-Pulsed Dendritic Cells for HER2+ and Triple Negative Breast Cancer Leptomeningeal Disease.

Peter Forsyth, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

P2-1-29

Trial in Progress: Phase 1, single-arm, open-label, multicenter trial to evaluate ovarian function suppression (OFS) following subcutaneous goserelin 10.8 mg in two parallel cohorts of premenopausal women with hormone receptor positive (HR+) breast cancer

Ami Chitalia, Medstar Washington Hospital Center, Washington, DC

P2-1-30

Predict-rd: ctdna-guided surveillance for postoperative molecular residual disease in triple-negative breast cancer with residual disease (tbcrc-071)

Yara Abdou, University of North Carolina at Chapel Hill, Chapel Hill, NC

P2-2-01

Fast mri: dyamond – a diagnostic yield study for women with average breast density in the nhs population-risk breast screening programme

Janet Audrey Dunn, University of Warwick, Coventry, United Kingdom

P2-2-02

[18f]fluorthanatrace positron emission tomography (ftt pet) for the measurement of parp tumor expression in patients with metastatic breast cancer

Jennifer Marie Specht, University of Washington/Fred Hutch Cancer Center, Seattle, WA

P2-2-03

A Randomized, Phase III Trial of Pre-Operative Window of Endocrine Therapy toInform Radiation Therapy Decisions in OlderWomen with Early-Stage Breast Cancer(POWER II)

Shayna Lefrak Showalter, University of Virginia, Charlottesville, VA

P2-2-04

CTC-EXPRESS: A prospective observational study for CTC biomarker Expression and cfDNA/cfRNA assessment in metastatic breast cancer

Padma Sri Katikaneni, UPMC, Pittsburgh, PA

P2-2-05

Clinical study of local and systemic biological impact of GLP-1/GIP receptor agonists in patients with breast cancer: the CLARA trial.

Josephine Van Cauwenberge, Catholic University of Leuven, Leuven, Belgium

P2-2-06

Imlunestrant and abemaciclib for the treatment of estrogen receptor-positive breast cancer in patients with minimal residual disease: MIRI Trial

Marla Lipsyc-Sharf, University of California Los Angeles, Los Angeles, CA

P2-2-07

Pulse trial: first-year enrollment results from the prospective cohort of dose-dense paclitaxel with empegfilgrastim in luminal b her2-negative early breast cancer

Nikolay Amirov, NMRC of Oncology named after N.N. Petrov, Saint Petersburg, Russian Federation

P2-2-08

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient-Reported Outcomes in Women with Hormone-Receptor-Positive Advanced Breast Cancer (FastER)

Tracy E Crane, University of Miami, Miami, FL

P2-2-09

Pre-ispy: a phase 1/2 platform trial for early drug development in MRD interception and advanced solid tumors (NCT05868226)

Jennifer R Diamond, University of Colorado Anschutz Medical Campus, Aurora, CO

P2-2-10

Ethan: A phase II study comparing different Endocrine THerapies for mAle breast caNcer.

Jose P Leone, Dana-Farber Cancer Institute, Boston, MA

P2-2-11

Trial in progress: A phase 2 randomized pilot study to develop tailored neoadjuvant chemoimmunotherapy strategies in stage I triple-negative breast cancer (DÉTENTE-1)

Nilesh Kapoor, UT Southwestern Medical Center, Dallas, TX

P2-2-12

Anthracycline-free Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer Patients with Cardiomyopathy or at an Elevated Risk of Cardiotoxicity (NeoCARD): A Response-adapted Single-arm Phase II Trial

Cara Coleman, Medical University of South Carolina, Charleston, SC

P2-2-13

Building a theory-grounded pretreatment education framework for metastatic breast cancer in community oncology: a multi-phase implementation science trial

Caroline Pardo, Integrated Action Science, LLC, Olathe, KS

P2-2-14

Signal-breast: setting international goals and research priorities for locoregional treatment in early breast cancer

Shelley Potter, Bristol Medical School, Bristol, United Kingdom

P2-2-15

Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01

Snehal Patel, Greenwich LifeSciences, Stafford, TX

P2-2-16

Sapanisertib and serabelisib (PIKTOR) with fulvestrant ± CDK4/6 Inhibitor in patients with HR+/HER2− advanced or metastatic breast cancer: A Phase 1b/2 study (FTH-PIK-101)

Amita Patnaik, START Center for Cancer Research, San Antonio, TX

P2-2-17

A phase III randomized, double-blind, placebo-controlled study of creatine supplementation to prevent chemotherapy-related cognitive decline in early-stage breast cancer (IARA trial)

Renata C Cangussu, Instituto D'Or de Pesquisa e Ensino (IDOR), Salvador, Brazil

P2-2-18

Evaluating the use of limb cryocompression to reduce taxane-induced peripheral neuropathy

Terri Jabaley, Dana-Farber Cancer Institute, Boston, MA

P2-2-19

Path-for-young optima/premenopausal extension: expanding optima randomized trial evidence for assay-directed chemotherapy decisions in premenopausal women with ER-positive/HER2-negative early breast cancer

Georgina Dotchin, University of Warwick, Coventry, United Kingdom

P2-2-20

An Implementation Trial Evaluating a Digital Shared Decision-Making Tool to Activate Older Adults with Metastatic Breast Cancer

Allison Magnuson, James P Wilmot Cancer Center, Rochester, NY

P2-2-21

Phase 1b study of novel combination of low dose oral cyclophosphamide (S) to potentiate axatilimab (A) + retifanlimab (R) in treating metastatic triple negative breast cancer (TNBC)

Angela Alexander, UT MD Anderson Cancer Center, Houston, TX

P2-2-22

Amxt1501-103 clinical trial: safety and efficacy of amxt 1501 in advanced breast cancer

Mark Robert Burns, Aminex Therapeutics, Inc., Kenmore, WA

P2-2-23

ItaberaÍ Randomized clinical trial: the challenge of developing an effective breast cancer screening system in low- and middle-income countries (LMICs)

Ruffo Freitas-Junior, Federal University of Goias, Goiânia, Brazil

P2-2-24

Kandela-302: a global phase 3 study evaluating efficacy and safety of the selective CDK4 inhibitor BGB-43395 with letrozole as a first-line therapy for patients with HR+/HER2- advanced or metastatic breast cancer

Shom Goel, Peter MacCallum Cancer Centre, Melbourne, Australia

P2-2-25

Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors: The I-MAMMO Study

Rachel A. Freedman, Dana-Farber Cancer Institute, Boston, MA

P2-2-26

Tadpole – targeted axillary dissection versus axillary node clearance in patients with positive axillary lymph nodes in early breast cancer: a multicentre, pragmatic, phase three randomized controlled trial

Shelley Potter, Bristol Medical School, Bristol, United Kingdom

P2-2-27

Trial in progress: A prospective randomized controlled phase III clinical trial evaluating the duration of lymphorrhea in breast cancer patients with clinical category N+ following radical mastectomy.

Alena Khodnevich, N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation

P2-2-28

Pikalo-2: a randomized phase 3 trial of tersolisib or placebo plus a cdk4/6 inhibitor and endocrine therapy as first-line treatment for pik3ca-mutated, hr+, her2- advanced breast cancer

Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, NY

P2-2-29

Zanidatamab in combination with tucatinib and chemotherapy in HER2-positive advanced breast cancer: the JAZMINE phase Ib/II trial

Giulia Notini, Medica Scientia Innovation Research (MEDSIR), Barcelona (Spain) and Cambridge (Massachusetts, USA); Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan,Italy; International Breast Cancer Center, Pangaea Oncology, Quirón Group, Barcelona, Spain

P2-2-30

Neoadjuvant trastuzumab deruxtecan followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) versus paclitaxel/docetaxel + carboplatin + trastuzumab + pertuzumab (TCHP), with response-guided post-neoadjuvant T-DXd in intermediate- to high-risk HER2+ early breast cancer (eBC): Cohort 3 (Part 2) of the WSG-ADAPT-HER2-IV trial

Nadia Harbeck, Breast Center, Department of Obstetrics and Gynecology and Comprehensive Cancer Center (CCC Munich LMU), LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany

P2-4-01

Multi-modal AI incorporating histology-inferred gene expression enables comprehensive breast cancer prognostication over a 10-year horizon

Kevin Kalinsky, Emory University, Atlanta, GA

P2-4-02

Comparison of a Multi-Modal AI Model to the 21-Gene Recurrence Score Assay in an External HR+/HER2- Breast Cancer Cohort

Mariam Haji, Roswell Park Comprehensive Cancer Center, Buffalo, NY

P2-4-03

Early Discontinuation of Adjuvant Endocrine Therapy (ET) Is Associated with Poorer Clinical Outcomes in Intermediate- and High-Risk HR+/HER2- Early Breast Cancer (eBC): A Real-World Analysis

Lisa A. Carey, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

P2-4-04

Impact of Immune-Related Adverse Events on Postoperative Outcomes Following Neoadjuvant Pembrolizumab in Early Triple-Negative Breast Cancer: A Real-World Cohort Study

Mahmoud Al-Masri, King Hussein Cancer Center, Amman, Jordan

P2-4-05

Social determinants of health (SDOH) detected and addressed by a deployed conversational artificial intelligence (AI): real-world evidence from 1,163 breast cancer patients (P) and care partners (CP)

Samira Daswani, Manta Cares, San Francisco, CA

P2-4-06

Real-world assessment of therapeutic sequencing for oral selective estrogen receptor degraders and PI3K/AKT pathway inhibitors in HR+/HER2− metastatic breast cancer with co-occurring ESR1 and PI3K-pathway alterations

Maxwell R Lloyd, Massachusetts General Hospital, Boston, MA

P2-4-07

Outcomes From an Integrated National Education and Multisite Quality Improvement (QI) Initiative in High-Risk HR+/HER2- Early Breast Cancer (EBC)

Kemi Obajimi, Decera Clinical Education, Reston, VA

P2-4-08

Clinical Characteristics, Prognostic Factors, Management, and Outcomes of Male Breast Cancer: The First Comprehensive Single-Center Report from the Middle East

Saad Akhtar, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

P2-4-09

Pregnancy-associated breast cancer hospitalizations: severe maternal morbidity, critical care utilization, and obstetric outcomes in the united states, 2016-2023

Charles Abraham Joseph Larson, Trinity School of Medicine, Warner Robins, GA

P2-4-10

Beyond SOUND: Heterogeneity of Macrometastatic Nodal Disease and Treatment Implications in Clinical T1N0 Breast Cancer

Mengni Guo, Loma Linda University, Loma Linda, CA

P2-4-11

A Real-World Analysis of Education During Treatment and Abemaciclib Persistence in HR+, HER2− Breast Cancer

Sara Nunnery, Tennessee Oncology, Nashville, TN

P2-4-12

Real World Tolerance of Diabetic Breast Cancer Patients to PIK3CA and mTOR Inhibitors

Sarah Adams, University of South Florida Morsani College of Medicine Medicine, Tampa, FL

P2-4-13

Unmasking the low-risk paradox: Real-world failure of the Clinical Index for Stable Febrile Neutropenia score, toxicity grading mismatches, and high prevalence of antimicrobial drug therapy problems in curative breast cancer patients in the emergency department

Christine Peragine, Sunnybrook Healh Sciences Centre, Toronto, ON, Canada

P2-4-14

Metabolic syndrome and oncologic outcomes in women with non-metastatic breast cancer: a real-world retrospective cohort study

Marcelo Antonini, Hospital do Servidor Publico estadual, Sao Paulo, Brazil

P2-4-15

First-line Real-world Outcomes in PIK3CA-mutant HR+, HER2- Advanced Breast Cancer in the US

Hope S Rugo, City of Hope Comprehensive Cancer Center, Duarte, CA

P2-4-16

Contemporary De-escalation of Locoregional Therapy in Patients with Extensive Nodal Involvement and Hormone Receptor-Positive/HER2-Negative Breast Cancer: A National Cancer Database Analysis

Jacquelyn Dillon, Mount Sinai Hospital, New York, NY

P2-4-17

Real-world safety profile, and management of interstitial lung disease (ILD) with trastuzumab deruxtecan in HER2-positive MBC: results from the multicenter observational ENHESUR cohort in Southern Spain

Ana Godoy-Ortiz, Hospital Universitario Virgen de la Victoria de Malaga, Málaga, Spain

P2-4-18

Endocrine Therapy (ET) Persistence Declines Progressively Over Ten Years (Yrs) and Non-Persistence is Associated with Worse Outcomes in Real-World (RW) Patients (Pts) with ER+, HER2− Early Breast Cancer (EBC) at Increased Risk of Recurrence

Seth Wander, Massachusetts General Hospital, Danvers, MA

P2-4-19

Clinicopathological Features, Treatment Patterns, and Survival Outcomes of Male Breast Cancer: A Large-Scale Multicenter Retrospective Study from 51 Japanese Institutions (OASIS Male BC)

Akihiko Shimomura, National Center for Global Health and Medicine, Tokyo, Japan

P2-4-20

Real-world effectiveness of trastuzumab deruxtecan versus chemotherapy in HER2-low metastatic breast cancer with visceral crisis: a multicenter comparative cohort study

Zheng Lv, First Hospital of Jilin University, Changchun, China

P2-4-21

The Clinical Paradox of Invasive Lobular Carcinoma: Dynamics of Late Recurrence and Risk of Second Primary MalignanciesThe Clinical Paradox of Invasive Lobular Carcinoma: Dynamics of Late Recurrence and Risk of Second Primary Malignancies.

Lucas Miranda, Universidade Federal de Alagoas, Arapiraca, Brazil

P2-4-22

Weight gain during KEYNOTE-522 based neoadjuvant chemoimmunotherapy for early triple-negative breast cancer: A contemporary real-world evaluation at The Royal Marsden NHS Foundation Trust in the United Kingdom.

Emma Crewe, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom

P2-4-23

Concomitant radiation therapy and sacituzumab govitecan in metastatic breast cancer patients: feasibility and outcomes from a real-life multicentre international cohort

Luca Visani, Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy

P2-4-24

Targeted Sentinel Node Biopsy (TSNB) in patients with needle biopsy proven nodal metastases undergoing primary surgery – initial results of the prospective NodeSMART study (ClinicalTrials.govNCT07085442)

Amit Goyal, Royal Derby Hospital, Derby, United Kingdom

P2-4-25

Interim analysis of PREDICT study: 7-gene biosignature and radiation benefit in DCIS

Patrick I Borgen, Maimonides Medical Center, Brooklyn, NY

P2-4-26

Breast cancer in pregnancy: does the trimester matter?

Stefan Lukac, Ulm University Hospital, Ulm, Germany

P2-4-27

Clinical Determinants of Survival in Male Breast Cancer: A 16-Year UK Cohort Study

Sunil Goyal, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

P2-4-28

Recurrence Patterns and Survival Outcomes in Patients (pts) with Early-Stage HR+/HER2- Breast Cancer Recurring on or After Adjuvant CDK4/6 Inhibitor Therapy: A Real-World Analysis

Julia Foldi, University of Pittsburgh School of Medicine, Pittsburgh, PA

P2-4-29

Cumulative incidence of CNS metastases after first-line THP in HER2+ metastatic breast cancer

Anna Sandoval Leon, Wertheim Cancer Institute, Baptist Health South Florida, Miami, FL

P2-4-30

Cumulative incidence of brain/CNS metastases by subtype and denovo vs recurrent presentation in metastatic breast cancer

Vikram Gorantla, Oncology Hematology Associates at University of Pittsburgh Medical Center, Pittsburgh, PA

P2-5-01

Comprehensive genomic profiling of patients with Invasive Lobular Carcinoma compared to Invasive Ductal Carcinoma in Hormone Receptor-Positive HER2-negative Breast Cancer; An interim analysis of the SONATA study (Real-world data of treatment patternS, Outcomes and geNomic profiling in eArly breasT cAncer in Greece, EUPAS1000000428)

George Douganiotis, European Interbalkan Medical Center, Thessaloniki, Greece

P2-5-02

Genomic risk can differentiate for adjuvant ribociclib/abemaciclib-eligible stage II ER+/HER2− breast cancer: A Belgian Cancer Registry Database

Karlien Wauters, University Hospitals Leuven, Leuven, Belgium

P2-5-03

Real-world gaps in trastuzumab deruxtecan adverse event management and community oncologist readiness in HER2-low/ultralow breast cancer: a controlled digital learning study

Caroline O. Pardo, Stitched Health, Bozeman, MT

P2-5-04

Sequential use of trastuzumab deruxtecan, sacituzumab govitecan, and datopotamab deruxtecan in metastatic breast cancer: Early real-world experience

Anna Sandoval Leon, Wertheim Cancer Institute, Baptist Health South Florida, Miami, FL

P2-5-05

Real-world maternal, oncologic, and perinatal outcomes of taxane-based chemotherapy during pregnancy in patients with breast cancer

Atsuko Kitano, St Luke's International Hospital, Tokyo, Japan

P2-5-06

Post-progression attrition in metastatic breast cancer: real-world evidence from the esme cohort

ALEXANDRE XU-VUILLARD, Gustave Roussy, Villejuif, France

P2-5-07

Anthracycline based chemotherapy is associated with an increased risk of metachronous contralateral breast cancer: a bicenter cohort study

Francisco Acevedo, Pontificia Universidad Catolica de Chile, Santiago, Chile

P2-5-09

Real-world Assessment of Hyperglycemia After PI3K, AKT, and mTOR Inhibitor Initiation in Patients with Breast Cancer

Maryam Mooghali, Yale School of Medicine, New Haven, CT

P2-5-10

Real-world use, variation and outcomes of radiotherapy omission after breast-conserving surgery in older women with low-risk breast cancer in England

Liyang Wang, Royal College of Surgeons of England, London, United Kingdom

P2-5-11

Impact of Pregnancy at Breast Cancer (BC) Diagnosis on Outcomes in Young BRCA1/2 Mutation Carriers

Agne Ozalinskaite, Klinik Hohe Warte, Bayreuth, Bayreuth, Germany

P2-5-12

Circadian IO Timing Improves EFS Without Increased Toxicity in Early-Stage Triple Negative Breast Cancer

Xianghui Zou, NYU Langone Health Long Island Perlmutter Cancer Center, Mineola, NY

P2-5-13

Age-stratified real-world safety of three antibody-drug conjugates in metastatic breast cancer

Jayasree Krishnan, Roswell Park Comprehensive Cancer Center, Buffalo, NY

P2-5-14

Association of Plasma-Detected PIK3CA Variant Class and Clonality With Real-World Outcomes After PI3K/AKT-Pathway Inhibitors in Advanced HR+/HER2- Breast Cancer

Shaheenah Dawood, Medicilinic Hospital, Dubai, United Arab Emirates

P2-5-15

Real-world breast cancer subtype prediction by plasma ctDNA methylation profiling across Asia and the Middle East

Shaheenah Dawood, Medicilinic Hospital, Dubai, United Arab Emirates

P2-5-16

Impact of a progesterone receptor-adjusted Nottingham Prognostic Index (iNPI) on genomic test risk classification in early breast cancer. Data from the Belgian Cancer Registry GEP-Database.

Karlien Wauters, University Hospitals Leuven, Leuven, Belgium

P2-5-17

Real-world durability of first-line Trastuzumab, pertuzumab, and taxane (THP) and the survival impact of endocrine therapy in HER2-positive (HER2+) metastatic breast cancer (mBC)

Saeed Rafii, Mediclinic City Hospital, Dubai, United Arab Emirates

P2-5-18

An EHR-embedded SmartForm utilized with ePROs to enhance structured oncology data capture and real-world evidence generation in breast cancer

Igor Makhlin, University of Pennsylvania, Philadelphia, PA

P2-5-19

Impact of GLP-1 Receptor Agonists on Five-Year Overall Survival in women with Breast Cancer treated with Tamoxifen or Letrozole: a retrospective analysis of nearly 20,000 patients

Franziska Fick, University of Luebeck, Lübeck, Germany

P2-5-20

Real-world outcomes of breast cancer central nervous system metastases treated with sacituzumab govitecan: a multi-institutional cohort study

Nira A Krasnow, University of California San Francisco, San Francisco, CA

P2-5-21

Real-world detection, molecular characterization, and clinical implications of emerging ESR1 mutations (ESR1m) during first-line (1L) treatment of hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC)

Jason A Mouabbi, The University of Texas, MD Anderson Cancer Center, Houston, TX

P2-5-22

Real-world (RW) characteristics, treatment (tx) patterns, and clinical outcomes in patients (pts) with HER2-positive metastatic breast cancer (HER2+ mBC)

Yuan Yuan, Cedars-Sinai Cancer, Beverly Hills, CA

P2-5-23

Unexpected sentinel lymph node metastasis in early lobular breast cancer – Results from a prospective real-world cohort

Elna Kuehnle, Hannover Medical School, Hannover, Germany

P2-5-24

Impact of Extracapsular Extension in Metastatic Sentinel Lymph Nodes on Breast Cancer Prognosis: A Systematic Review and Meta-Analysis

Beatriz Westphalen Pomianoski, A.C. Camargo Cancer Center, Sao Paulo, Brazil

P2-5-25

Real-world tolerability and dose modification with adjuvant abemaciclib in HR+, HER2-, node-positive early breast cancer in the US

Caleb Paydar, Cardinal Health, Dublin, OH

P2-5-26

Susan G. Komen®’s ShareForCures® integrates real-world data to better understand patients’ experiences, care, and outcomes

Arlen Larry Gyden, Susan G. Komen, Dallas, TX

P2-5-27

Time Since Childbirth and Breast Cancer Prognosis in 2,415 Young Women: A Prospective GBG BCP Registry Study

Philipp Meyer-Wilmes, University Hospital RWTH Aachen, Aachen, Germany

P2-5-28

Cost-effectiveness of cdk4/6 inhibitors for hr-positive/her2-negative metastatic breast cancer in brazil: results from the breast trial (brazilian outcome for metastatic breast cancer)

Luciola Pontes Leite de Barros, HCor Research Institute, Sao Paulo, Brazil

P2-5-29

Evaluating Digital Twin Models Using the FDA ENCORE Real‑World Trial Emulation Framework in Triple‑Negative Breast Cancer Patients

Chi T Truong, Evinexus, Raleigh, NC

P2-5-30

Changes in practice patterns have resulted in proportionally fewer patients with 4 or more positive lymph nodes, which may contribute to a Will Rogers phenomenon.

Vincent Baltera, University of Southern California, Los Angeles, CA

P2-7-01

Anatomic Tumor Location and Metastatic Disease Burden Among Breast Cancer Hospitalizations in the United States: A National Inpatient Sample Analysis, 2016-2023

Selena Lwin, Comprehensive Cancer Centers of Nevada, Central Valley–Twain, Las Vegas, NV

P2-7-02

Real-world integration of the breast cancer index in endocrine therapy management.

Angela Yang, Icahn School of Medicine at Mount Sinai, New York, NY

P2-7-03

Long-term persistence and dose modifications with adjuvant abemaciclib in HR+, HER2-, node-positive early breast cancer

Susan F. Dent, University of Rochester,, Rochester, NY, NY

P2-7-04

Reduced contralateral breast cancer risk following adjuvant endocrine therapy in patients with primary estrogen receptor-positive breast cancer: Real-world evidence from an integrated healthcare system

Gretchen L Gierach, National Cancer Institute, Bethesda, MD

P2-7-05

Stereotactic Body Radiotherapy as Metastasis Directed Therapy for synchronous bone-only oligometastatic breast cancer treated with curative intent: real-world outcomes and predictors of progression-free survival

Abhilash Dagar, All India Institute of Medical Sciences,New Delhi, New Delhi, India

P2-7-06

Treatment strategies and outcomes of breast cancer during pregnancy: a multicenter real-world CEBCC-01 study

Zuzana Bielcikova, First Faculty of Medicine, Charles University, and General University Hospital, Prague, Czech Republic

P2-7-07

Utilization Trends and Comparative Effectiveness of Adjuvant Zoledronic Acid Versus Denosumab in Early-Stage Breast Cancer: A Real-World TriNetX Cohort Study

Ansy Patel, SUNY Upstate Medical University, Syracuse, NY

P2-7-08

Nyu-adapt Breast: a pragmatic, routine care-embedded ctDNA/MRD tumor monitoring platform across the breast cancer continuum

Neil Vasan, NYU Langone Health, New York, NY

P2-7-09

Eligibility and Prognostic Impact of Current Adjuvant CDK4/6 Inhibitors in HR+/HER2− Early Breast Cancer: The First Real-World Comparison of NATALEE, monarchE, and DAWNA-A in Southern China

Tiancheng He, The First People's Hospital of Foshan (Foshan Hospital Affiliated to Southern University of Science and Technology), School of Medicine, Southern University of Science and Technology, Foshan, China

P2-7-10

Treatment Expectations in Patients Initiating Adjuvant CDK4/6 Inhibitor Treatment for High-Risk HR+/HER2− Early Breast Cancer in the Real-World Non-Interventional CAROLEEN Study

Michael P Lux, Women's Clinic St. Louise, Paderborn and St. Josefs Hospital, Salzkotten, St. Vincenz Clinics GmbH, Paderborn, Germany

P2-7-11

Stage specific molecular evolution across early-stage and metastatic triple-negative breast cancer

Madhuri Paul, NeoGenomics Laboratories, Aliso Viejo, CA

P2-7-12

Glp-1r agonist exposure is associated with lower rates of disease progression and mortality in breast cancer patients

Luxi Chen, Cedars-Sinai Medical Center, Los Angeles, CA

P2-7-13

Real-World Efficacy Outcomes With Tucatinib for HER2-Positive Advanced Breast Cancer (ABC) Immediately After Trastuzumab deruxtecan (SOLTI-2309 RESISTHER)

Rodrigo Sánchez-Bayona, University Hospital 12 De Octubre/SOLTI Cancer Research Group, Madrid, Spain

P2-7-14

Real-world survival outcomes of ribociclib plus endocrine therapy in HR+/HER2-negative advanced breast cancer: a national cohort study from Uruguay

Natalia Camejo, Hospital de Clinicas, Montevideo, Uruguay

P2-7-15

Neoadjuvant endocrine therapy is associated with reduced upstaging of DCIS during >90-day surgical delays

Lauren Fang, Mayo Clinic, Rochester, MN

P2-7-16

Treatment Rechallenge After Recovery from Antibody-Drug Conjugate (ADC)-Related Interstitial Lung Disease (ILD) in Patients with Metastatic Breast Cancer (MBC)

Thanate Dajsakdipon, European Institute of Oncology, IRCCS, Milan, Italy

P2-7-17

Triple Negative Breast Neuroendocrine Carcinoma (TN Br-NEC): an aggressive subtype with poor response to systemic therapy

Elyse Rose Lopez, University of Texas MD Anderson Cancer Center, Houston, TX

P2-7-18

Life after antibody-drug conjugates: does prior sacituzumab govitecan or trastuzumab deruxtecan blunt the next chemotherapy?

Filippo Giovanardi, IRCCS AUSL Reggio Emilia, Reggio Emilia, Italy

P2-7-19

Biennial mammography adherence and five-year survival among Colombian women with breast cancer: a retrospective cohort study using linked national administrative databases

Andrés F Patiño-Benavidez, Fundación Cardioinfantil-Instituto de Cardiología, Bogota, Colombia

P2-7-20

Investigating Weight Change and Survival Outcomes after GLP-1 Receptor Agonist Therapy among Patients with Breast Cancer

Armaan Jamal, University of Chicago, Chicago, IL

P2-7-21

Receptor change between primary breast cancer and locoregionally recurrent breast cancer – a Real-World Analysis

Maëlys Yepes, Cleveland Clinic Foundation, Cleveland, OH

P2-7-22

Androgen Receptor expression in early breast cancer: a real-world analysis across breast cancer subtypes

Claudia Senatore, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

P2-7-23

Survival and Cardiovascular Outcomes with GLP-1 Receptor Agonists in Women with Breast Cancer Receiving Endocrine Therapy

Oluwadamilola T Oladeru, Mayo Clinic Florida, Jacksonville, FL

P2-7-24

Treatment evolution, attrition, outcomes, and prognostic factors in HR+/HER2− metastatic breast cancer: the Spanish registry, GEICAM/2014-03 (RegistEM)

Sara López-Tarruella, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Universidad Complutense, Madrid, SPAIN; GEICAM, Spanish Breast Cancer Group, Madrid, Spain

P2-7-25

Comparative hematologic safety of Trastuzumab Deruxtecan and Paclitaxel in metastatic hormone receptor-positive, HER2-low breast cancer: Real-world evidence from TriNetX

Sumbal Aziz, AdventHealth, Sebring, FL

P2-7-26

Spectrum and Clinical Impact of irAEs in ICI-Treated TNBC: The MIRAE Prospective Cohort

Erika Bushatsky Andrade de Alencar, Jewish General Hospital, McGill University, Montreal, QC, Canada

P2-7-27

Immune-related adverse events in real-world triple-negative breast cancer treated with neoadjuvant pembrolizumab

Abhinav A Vayal Veettil, Cleveland Clinic Foundation, Cleveland, OH

P2-7-28

Characteristics and Prognosis of Patients with Metachronous Contralateral Breast Cancer

Vasily Giannakeas, Women's College Hospital, Toronto, ON, Canada

P2-7-29

Access barriers and peri-procedure interruptions, not intolerance, shape GLP-1 receptor agonist continuity in breast cancer: a real-world EHR study

Fah Sathirapongsasuti, Novellia, New York, NY

P2-7-30

Tripoli study: real-world characteristics, treatment patterns, and outcomes of triple-negative breast cancer across 5 arab countries

Bernadette Pöllinger, MSD Sharp & Dohme, München, Germany

P2-8-01

Real-world treatment patterns and outcomes by pathologic complete response (pCR) status in early-stage triple-negative breast cancer (eTNBC)

Aaron Peevyhouse, ONCare Alliance, Tacoma, WA

P2-8-02

Contemporary Therapy for Small Node-Negative Triple-Negative Breast Cancer: A Retrospective Cohort Study

Brian Seyeon Lee, University of Texas Southwestern Medical Center, Dallas, TX

P2-8-04

Pathologic complete response and clinical predictors in real-world patients receiving the KEYNOTE-522 regimen for early-stage triple-negative breast cancer

Stephanie Adel Haddad, UT Health San Antonio/Mays Cancer Center, San Antonio, TX

P2-8-05

Anthracycline-free versus Anthracycline-based neoadjuvant dual anti-HER2 therapy and pathologic complete response (pCR) in HER2-positive breast cancer: A propensity score-matched real-world study

Hikmat Abdel-Razeq, King Hussein Cancer Center, Amman, Jordan

P2-8-06

The Evolving Landscape of Breast Cancer with Brain Metastases: Insight from a 10-Year Real-World Analysis

Laura Cortesi, University of Modena and Reggio Emilia, Modena, Italy

P2-8-07

Real-world use of ctDNA testing in patients with HR+/HER2- breast cancer who received a 21-gene test result

Tara Marti, Abbott, Madison, WI

P2-8-08

Survival outcomes following trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer (HER2+ mBC) in a 3L/3L+ cohort: a systematic literature review

Alex Bates, Jazz Pharmaceuticals, London, United Kingdom

P2-8-10

Clinicopathologic Concordance of Skin Involvement in cT4b Breast Cancer: A 521-Patient Real-World Cohort

Xinyi Quan, Fudan University Shanghai Cancer Center, Shanghai, China

P2-8-11

Treatment Patterns and Clinical Outcomes of the Trop 2 Antibody Drug Conjugates Sacituzumab Govitecan and Sacituzumab Tirumotecan in HER2 Negative Advanced Breast Cancer: A Multicenter Real World Study in China

Bin Shao, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China

P2-8-12

Real-world treatment patterns and overall survival for patients with HR+ and HER2-low or HER2-ultralow/null metastatic breast cancer receiving standard of care post-endocrine therapy: a retrospective observational study using US electronic medical records

Tiffany A Traina, Memorial Sloan Kettering Cancer Center, New York, NY

P2-8-13

Chemotherapy regimen and estrogen receptor-specific contralateral breast cancer risk in a contemporary cohort of breast cancer survivors

Lene H.S. Veiga, National Cancer Institute, Rockville, MD

P2-8-14

Real-world comparison of antibody-drug conjugates efficacy in patients with advanced invasive lobular carcinoma and invasive ductal carcinoma

Claudia von Arx, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy

P2-8-15

Role of UGT1A1 Pharmacogenetics in Breast Cancer Patients Treated with Sacituzumab Govitecan: Updated Real-World Experience from a Single Institution

Marta Andres Granyo, Hospital Santa Creu i Sant Pau, Barcelona, Spain

P2-8-16

Breastorm: a multicenter real-world study of sacituzumab govitecan safety and efficacy in metastatic tnbc and hr+/her2− breast cancer

Jessica Paparo, Institut Gustave Roussy, Villejuif, Francia, France

P2-8-17

Real-world procurement lead time for reduced-dose palbociclib and abemaciclib in HR+/HER2− metastatic breast cancer in Russia

Alexander Petrovsky, N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation

P2-8-19

Distribution of de novo versus recurrent metastatic breast cancer by year of metastatic diagnosis and breast cancer subtype: results from the AGMT_MBC-registry.

Vanessa Castagnaviz, Paracelsus Medical University Salzburg, Salzburg, Austria

P2-8-20

Histologic Subtype and Overall Survival in Patients Treated with Trastuzumab Deruxtecan: A Real-World Analysis of Invasive Lobular versus Invasive Ductal Carcinoma

Pooja P Advani, Mayo Clinic, Jacksonville, FL

P2-8-21

Long-term clinical outcomes according to estrogen receptor expression level in metastatic breast cancer: potential therapeutic implications

Yumi Wanifuchi-Endo, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

P2-8-22

Clinical and Genomic Risk Concordance, Chemotherapy Utilisation, and Outcomes Following Oncotype DX Testing-A Retrospective Single-Centre Audit of 297 Patients

Ruba Ahmed Hamed, Northern Ireland Cancer Centre, Belfast, United Kingdom

P2-8-23

Neoadjuvant Chemotherapy Utilization and Pathologic Complete Response in Early-Stage Invasive Lobular Carcinoma: Real-World Data

Hikmat Abdel-Razeq, King Hussein Cancer Center, Amman, Jordan

P2-8-24

Real-world outcomes of trastuzumab deruxtecan and sacituzumab govitecan according to treatment-line positioning in the ESME metastatic breast cancer database

Alexandre de Nonneville, Institut Paoli-Calmettes, Marseille, France

P2-8-25

Clinicopathological characteristics and prognostic analysis of metaplastic breast carcinoma: a large-sample, multi-center study from china

Zejian Yang, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

P2-8-26

Real-world performance and clinical impact of an in-house tumour-agnostic next-generation sequencing (NGS) program in hormone receptor-positive HER2-negative metastatic breast cancer

Sophie Richard, BC Cancer, Vancouver, BC, Canada

P2-8-27

Clinical and molecular characteristics of triple-negative breast cancer in patients with hyperglycemia and type 2 diabetes mellitus: A real-world clinico-genomic analysis

Jasmin Hundal, Emory Univeristy, Atlanta, GA

P2-8-28

Real-world trends in breast cancer incidence and mortality: a nationwide population-based analysis, 2020-2024

Balazs Gyorffy, Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary

P2-8-29

Real-world experience with talazoparib in her2-negative brca-mut metastatic breast cancer in Russian Federation: efficacy, safety, and the impact of late brca testing

Elena V. Lubennikova, Federal State Budgetary Institution «N.N. Blokhin National Medical Research Center of Oncology », Ministry of Health of Russia, Moscow, Russian Federation

P2-8-30

Maintenance Endocrine Therapy Following Pertuzumab, Trastuzumab and Taxane Induction in HER2+/HR+ Metastatic Breast Cancer: An Emulation of a Sequence of Target Trials.

Thibaut Sanglier, F.Hoffmann-La Roche Ltd, Basel, Switzerland

P2-3-01

Unphosphorylated PEA-15 Drives Immune Activation Through Modulation of the PKA/β-Catenin Axis in Triple-Negative and Inflammatory Breast Cancer

Mafia Mahabub Rumpa, University of Texas MD Anderson Cancer Center, Houston, TX

P2-3-02

Potential role of bile acid signaling in pembrolizumab response and tumor immune activity in breast cancer: an integrated analysis of I-SPY2 and 8 independent cohorts

Toru Hanamura, Tokai University School of Medicine, Isehara, Japan

P2-3-03

Tumor Microenvironment Reprogramming by γ-Secretase Inhibition Potentiates Radiotherapy and Checkpoint Blockade in TNBC

Eileen P Connolly, Columbia University Medical Center, New York, NY

P2-3-04

Human Ductal Carcinoma in Situ: Mechanism of Early Dissemination and Metastasis.

Reagan Henry, University of Kansas Medical Center, Kansas City, KS

P2-3-05

Targeting FOXM1 to enhance immune memory and develop a therapeutic cancer vaccine for triple negative breast cancer

Jian Huang, UT Health San Antonio, San Antonio, TX

P2-3-07

Multi-compartment profiling identifies mature regulatory dendritic cells as a conserved immune state associated with effective anti-tumour immunity in early breast cancer

Sheeba Irshad, King's College London, London, United Kingdom

P2-3-08

Pyrimidine inhibition reprograms suppressive myeloid phenotype in breast cancer

Brian G Morreale, UT MD Anderson, Houston, TX

P2-3-09

Spatial single-cell transcriptomic analysis reveals obesity-associated macrophage reprogramming in triple-negative breast cancer

Andrew Liu, Rice University, Houston, TX

P2-3-11

Senescent Whole-Cell Vaccines for Overcoming Resistance in Breast Cancer

Sara Rasouli, The Ohio State University, Columbus, OH

P2-3-12

Post-capillary venule endothelial signature predicts clinical outcome and immune checkpoint inhibitors (ici) response in triple-negative breast cancer (tnbc)

Saranya Chumsri, Mayo Clinic, Jackcsonville, FL

P2-3-13

Epigenetic suppression of tumor-specific MHC-II as a driver of immune checkpoint inhibitor resistance in TNBC

Joseph A. Serrenho, Vanderbilt University, Nashville, TN

P2-3-14

Safety of a MUC1 Peptide Vaccine with Hiltonol®Adjuvant as an Immune Interception Strategy in Ductal Carcinoma In Situ: Interim Results from a Phase Ib Randomized Trial

Emilia J Diego, University of Pittsburgh, Pittsburgh, PA

P2-3-17

Obesity associated Estrogen:NFκB cooperation drives NK cell impairment in Estrogen Receptor Positive Breast Cancer

Miriam T Jacobs, Georgetown University, Lombardi Comprehensive Cancer Center, WASHINGTON, DC

P2-3-18

Denosumab as an immune modulator: results of a window-of-opportunity study in early breast cancer.

John Ross Kucharczyk, NYU Langone Health, Mineola, NY

P2-3-19

Identification of seven CAF subsets and their predictive value for recurrence and radiotherapy response in a randomized trial of early-stage breast cancer

Amalia H Landén, Institute of Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden

P2-3-20

Programmed Death-Ligand 2 (PD-L2)-high antigen-presenting cell niches define recurrence-associated spatial immune architecture in triple-negative breast cancer

Thanpisit Lomphithak, Massachusetts General Hospital, Boston, MA

P2-3-21

Single cell and spatial transcriptomics define a CAF myeloid niche associated with impaired cytotoxic immunity in metaplastic breast cancer

Yidi Wang, the First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China

P2-3-22

Targeting PHGDH restores anti-tumor immunity and sensitizes triple-negative breast cancer to anti-PD-L1 therapy

Hui Lyu, Louisiana State University Health Sciences Center, new orleans, LA

P2-3-23

Post-partum breast cancer patient derived extracellular vesicles contain pro-metastatic, anti-immunosurveillance protein cargo, which correlates with a pro-tumor, pro-angiogenic serum cytokine profile.

Travis M Walrath, University of Colorado Anschutz Medical Campus, Aurora, CO

P2-3-24

Quantitative and qualitative significance of tertiary lymphoid structures in response to neoadjuvant chemotherapy for breast cancer

Sayumi Imamura, Osaka University Graduate School of Medicine, Suita-city, Osaka, Japan

P2-3-25

Comparing the spatial immune architecture in large, high-risk ductal carcinoma in situ to molecularly matched invasive breast cancer

Joshua Barkin, UCSF, San Francisco, CA

P2-3-26

Anti-rankl decreases breast cancer bone metastases while increasing bone volume, but enriches immunosuppressive myeloid populations in the bone marrow

Jailyn Smith, Vanderbilt University, Nashville, TN

P2-3-27

Age and tumor microenvironment informs anti-PD-1 efficacy for primary tumors but does not reduce metastatic spread in mice with TNBC

Ava Marie Jessen, University of California, Davis, Sacramento, CA

P2-3-28

A spatially annotated intratumoral nerve signature is associated with low-proliferative tumors with a dysfunctional immune microenvironment in triple-negative breast cancer

Kei Kawashima, Roswellpark Comprehensive Cancer Center, Buffalo, NY

P2-3-29

From Cold to Hot: Exposing ER Stress as a Targetable Mediator of Immune Suppression in Breast Cancer Liver Metastases

Michelle M. Williams, University of Pittsburgh, Pittsburgh, PA

P2-3-30

Association of High Cxcl9 and Cxcr3 With Chemotherapy but not Antibody-Drug Conjugate Benefit in Triple-Negative Breast Cancer: A Real-World Analysis

Shipra Gandhi, Winship Cancer Institute of Emory University, Atlanta, GA

P2-6-01

Combined PARP inhibition and immune checkpoint blockade elicit differentially improved survival in BRCA1, BRCA2, PALB2 vs CHEK2, ATM deficient breast cancer by promoting an anti-tumor immune response through tertiary lymphoid structure formation

Sibapriya Chaudhuri, University of California San Francisco, San Francisco, CA

P2-6-02

Functional proteomic profiling of tumor stroma in the I-SPY2 TRIAL suggests HR/HER2 biology does not strongly influence stroma microenvironment and uncovers new targetable biology of resistance and recurrence

Denise M Wolf, University of California, San Francisco, San Francisco, CA

P2-6-03

Exploring ISR induced immune evasion in breast cancer

Isabella Terrazas, UT Southwestern Medical Center, Dallas, TX

P2-6-04

Cdk4/6 inhibitors reverse tumour-educated inflammatory immune changes in breast cancer

Olesya A. Kharenko, Syantra Inc, Calgary, AB, Canada

P2-6-05

Hyperlipidemia-induced adipose hypoxia drives breast cancer progression via hif-1α/slc25a1-mediated metabolic rewiring and pro-tumorigenic exosomes

Ziling Zhou, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

P2-6-06

A QuPath-MATLAB pipeline for single-cell and spatial analysis of 40-plex immunofluorescence for interrogation of high-risk young onset and postpartum breast cancers.

Brendan Hinckley, University of Colorado Anschutz Medical Campus, Aurora, CO

P2-6-08

Flow cytometry-defined tumor-infiltrating lymphocyte subpopulations and pathological response to neoadjuvant chemotherapy in HER2-negative breast cancer

Elena Artamonova, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation

P2-6-09

Integration of network toxicology and single-cell RNA sequencing to identify key genes with pharmaceutical and personal care product signatures in breast cancer and characterize their prognostic and immunological traits

Wei Chen, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China

P2-6-10

Age-related extracellular matrix remodeling in primary human breast adipose tissue identifies periostin as a young matrisome protein associated with hr+ breast cancer progression

Mackenzie Hawes, Tulane University, New Orleans, LA

P2-6-11

Dissecting the NR4A1-KLRG1 Regulatory and Functional Axis in Reprogrammed NK cells within the Breast Tumor Microenvironment

Libi Anandi Viswanathan, UT Southwestern Medical Center, Dallas, TX

P2-6-12

Spatial Immune Landscapes in Breast Cancer from Tanzania versus the United States

Nashivai Kivuyo, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania, United Republic of

P2-6-14

Development of breast-adipose co-culture model to decipher the impact of lipid heterogeneity on triple-negative breast cancer progression

Khudeja Salim, Tulane University, New Orleans, LA

P2-6-15

Obesity-associated peripheral T-cell remodeling during neoadjuvant chemoimmunotherapy in early-stage triple-negative breast cancer

Jasmin Hundal, Emory Winship Cancer Institute, Atlanta, GA

P2-6-16

Memory-like differentiation and ephA2 chimeric antigen receptor engineering synergistically enhance natural killer cell activity against triple negative breast cancer

Miriam T Jacobs, Georgetown University, Lombardi Comprehensive Cancer Center, Washington, DC

P2-6-17

Isg15-positive cancer-associated fibroblast-derived exosomal pfkfb3 drives invasion and immune remodeling in triple-negative breast cancer

Fangzhou Ye, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

P2-6-18

Establishment of an in vitro assay modeling breast cancer vessel co-option and identification of VE-cadherin-dependent endothelial adhesion

Masafumi Shimoda, Hyogo Medical University, Nishinomiya, Japan

P2-6-19

Radiotherapy-induced nanomechanical remodeling and immune spatial organization in fungating breast cancer: interim results from the prospective BRIGHT-RAD study

Qiong Gan, UT MD Anderson Cancer Center, Houston, TX

P2-6-21

Demonstration of Unique Repertoire and Specific Utilization of B-cell and T-cell Receptors in Metastatic Breast Cancer Using Liquid Biopsy

Julia Foldi, University of Pittsburgh School of Medicine, Pittsburgh, PA

P2-6-22

Cd90 regulates extracellular vesicle biology and tumor endothelial communication in triple-negative breast cancer

Leticia A Fernandes, Boston University, Boston, MA

P2-6-23

Soluble E‑cadherin promotes immune cell-mediated cytotoxicity despite CD95 suppression

Lan Phi, MD Anderson Cancer Center, Houston, TX

P2-6-24

Postpartum breast cancer exhibits distinct immune, stromal and cell-cell communication programs

Vidya P Nimbalkar, St. John’s Research Institute, St. John’s Medical College, Bangalore, Karnataka, India, India

P2-6-25

Epithelial Integrity and Stromal Remodeling Distinguish Ductal Carcinoma In Situ with High-Risk of Recurrence

Joshua Barkin, UCSF, San Francisco, CA

P2-6-27

Macrophage CXCL9:SPP1 polarization inverts across metastatic sites and serves as a pan-subtype prognostic marker of breast cancer

Batul Al-Zubeidy, University of Southern California, Los Angeles, CA

P2-6-28

Tetraspanin 5 expressing macrophages promote breast cancer

Joseph Priestley, University of Sheffield, Sheffield, United Kingdom

P2-6-29

A novel histopathological classification of tertiary lymphoid structures identifies vascularized TLS as a potential subtype in breast cancer

Esther Sanfeliu Torres, Hospital Clínic of Barcelona, Barcelona, Spain

P2-6-30

Whole transcriptome spatial profiling in a single FFPE breast section reveals a coordinated invasive front gene program shared across high-grade 11q13-amplified tumor, reactive myoepithelium, and myofibroblastic CAFs.

Amanda Janesick, 10x Genomics, Pleasanton, CA

P2-9-01

Complementary in vivo genetic approaches to define mechanisms of trastuzumab deruxtecan resistance in an immunologic context

Stella Feliciello, Vanderbilt University Medical Center, Nashville, TN

P2-9-03

Combined MEK/PI3K inhibition reveals an immunotherapy-permissive tumor microenvironment and metabolic liabilities in PIK3R1-mutant TNBC PDX models

Jeffrey Borgia, Rush University, Chicago, IL

P2-9-04

Role of the PI3K/AKT/mPOR pathway in HER2-directed treatment resistance and tumor immunity in HER2-positive breast cancer

Ju Won Kim, Korea University College of Medicine, Seoul, Korea, Republic of

P2-9-05

Role of Liver Kinase B1 and its downstream kinases as regulators of estrogen receptor signaling in estrogen receptor-positive breast cancer

Bakhtawar Tufail, Tulane University, New Orleans, LA

P2-9-06

Early on-treatment transcriptomic programs associated with resistance to palbociclib-based endocrine therapy in HR-positive/HER2-negative breast cancer

Xiaoyun Mao, The First Affiliated Hospital of China Medical University, Shenyang, China

P2-9-07

Paired Germline and Tumor Whole Exome Sequencing Reveals Candidate Genomic Determinants of Response to Neoadjuvant Chemotherapy in Breast Cancer

Selman Emiroglu, Istanbul University, Istanbul, Turkey

P2-9-08

Low-dose MEK1/2 and AKT inhibition: An innovative strategy to overcome therapeutic resistance in triple-negative breast cancer

Margarite Matossian, University of Chicago, Chicago, IL

P2-9-09

Unraveling PARP inhibitor resistance through single-cell mapping of BRCA1 reversion mutations

Steven R Vandal, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

P2-9-10

Pten loss disrupts mitophagy and reshapes cellular bioenergetics in tnbc models exposed to sacituzumab govitecan

Roberta Caputo, INT IRCSS Fondazione G. Pascale, Napoli, Italy

P2-9-11

Copper Chelation and Antioestrogen Tamoxifen: Overcoming Resistance in ER+ Breast Cancer

Piper Rose Schadel, University of New South Wales, Sydney, Australia

P2-9-12

Platinum-induced NORAD expression confers chemoresistance in breast cancer by modulating p53 dynamics

Huan Li, Peking University People's Hospital;Beijing Key Laboratory of AI-Enabled Data Governance and Precision Medicine for Breast Cancer, Beijing, China

P2-9-13

Emerging epigenetic targets during chemotherapy resistance progression in triple negative breast cancer

Liliana Garcia, University of Miami, Miami, FL

P2-9-14

Epigenetic reactivation of PPP3CB by HDAC inhibition restores HER2-targeted therapy sensitivity in resistant HER2-positive breast cancer

Congcong Tan, LSUHSC, New Orleans, LA

P2-9-15

3d chromatin reorganization contributes to resistance to cdk4/6 inhibitor in er+ breast cancer

Felice Pepe, University of Naples Federico II, Naples, Italy

P2-9-16

Cdk2 inhibition reveals a distinct 4n arrest state in er+/her2- breast cancer cells

Leah K Frazier, University of North Carolina at Chapel Hill, Chapel Hill, NC

P2-9-17

Enhancer-promoter looping mediated carbonic anhydrase 2 regulates metabolic reprogramming in tamoxifen-resistant breast cancer

Lavanya Choppavarapu, Medical college of Wisconsin, Milwaukee, WI

P2-9-18

Characterization of Autophagy Induction by Capivasertib and Inavolisib: A Potential Mechanism of Drug Resistance

Maria Zeb, Scuola Superiore Merdionale, Napoli, Italy

P2-9-19

Lmtk2 coordinates akt/er signaling to promote endocrine resistance in er-positive breast cancer

Anna Detry, Mayo Clinic, Rochester, MN

P2-9-20

Investigating Chromatin Remodeling as a Therapeutic Vulnerability in ESR1 Mutant Breast Cancer

Autumn GM Hawkins, Baylor College of Medicine, Houston, TX

P2-9-21

Mechanism underlying allele bias of a novel estrogen receptor mutation

Utthara Nayar, Johns Hopkins University, Baltimore, MD

P2-9-22

G-quadruplexes as resistance drivers and therapeutic vulnerabilities in advanced ERα+ breast cancer

Michael Emch, Mayo Clinic, Rochester, MN

P2-9-23

Type 2 Diabetic Plasma-Derived Exosomes Promote Chemoresistance and Aggressive Phenotypes in ER+ Breast Cancer Cells

Austyn Smithback, Boston University School of Medicine, Boston, MA

P2-9-25

Identification of BHLHE40 as a novel driver of endocrine/CDK4/6i resistance

Jenna Heinen, Mayo Clinic, Rochester, MN

P2-10-01

Clinical Utility of<sup>18</sup>F-Fluoroestradiol (FES) PET in Surgical Patients with Early-Stage Invasive Lobular Carcinoma (ILC)

Jason Mouabbi, UT MD Anderson, Houston, TX

P2-10-02

Libra-measured quantitative breast density as a potential biomarker of response to adjuvant endocrine therapy in women with operable hormone receptor-positive breast cancer

Preeti Kakani, Columbia University Irving Medical Center, New York, NY

P2-10-03

Early and Alternative FDG-PET/CT Metrics to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer: ECOG-ACRIN EA1183 (FEATURE) Trial

Jennifer M Specht, University of Washington/Fred Hutch Cancer Center, Seattle, WA

P2-10-04

Women’S and men’s perspectives on breast cancer in Turkiye: Strategies to improve screening participation – a cross-sectional study

Ece Dilege, Koç University, School of Medicine, Istanbul, Turkey

P2-10-05

Early diagnostic and neoadjuvant therapy response assessment in inflammatory breast cancer using mammography-derived global skin thickness measurements

Carlos A Gallegos, UT MD Anderson Cancer Center, Houston, TX

P2-10-06

A novel blood-based lipidomic assay for the loco-regional breast cancer recurrence

David Speakman, BCAL Diagnostics, Sydney, Australia

P2-10-07

Diagnostic Mammography assessments with Color-Enhanced AI CADx: Initial Pilot Study of Color Mapping enhanced lesion analysis across BI-RADS categories

Chirag Parghi, Jefferson Health-Lehigh Valley, Allentown, PA

P2-10-09

<sup>64</sup>Cu-dota-trastuzumab-pet

Joanne E. Mortimer, City of Hope National Medical Cancer Center, Duarte, CA

P2-10-10

The colors of Breast Cancer: A pictoral essay spotlighting the utility of Color Enhanced AI CADx on multimodality imaging of breast cancer.

Chirag Parghi, Jefferson Health-Lehigh Valley, Allentown, PA

P2-10-11

Breast Cancer Risk Stratification Using the Gail Model and Its Association with Screening Behaviors Among Syrian Women: A National Cross-Sectional Study.

Hira Munir, Advocate Health Care, Chicago, IL

P2-10-12

Breast Density and Abnormal Mammographic Findings in Brazil’s Public Mammography Registry A Nationwide Analysis, 2015-2025

Marcelo Antonini, Hospital do Servidor Publico estadual, Sao Paulo, Brazil

P2-10-13

Single center experience of simultaneous 18F Fluoroestradiol PET-MRI for hepatobiliary and soft tissue assessment of ER+ breast cancer

Catherine Bullock, Mayo Clinic Jacksonville, Jacksonville, FL

P2-10-14

Plasma-based Deep Proteome Profiling for Early Breast Cancer Detection in Women Undergoing Biopsy: An Interim Analysis

Justin M. Drake, Astrin Biosciences, St. Paul, MN

P2-10-15

Contrast Enhanced Mammography for Response Assessment After Neoadjuvant Chemotherapy in Breast Cancer

Anna Andrzejczyk, Stony Brook University Hospital, Stony Brook, NY

P2-10-16

Omission of Nodal Staging Requires Institutional Validation

Jared Su, Stanford University, Stanford, CA

P2-10-17

Development and Validation of a Nomogram for Pre-Biopsy Prediction of Breast Cancer in Patients with Nipple Discharge

Junhan Li, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China

P2-10-18

Malignancy predictive ultrasound features of axillary lymph nodes: preliminary results of a quality improvement study on the malignancy rate of ultrasound-guided axillary lymph node biopsies at a single institution

Monica L Huang, The University of Texas Health Sciences Center at Houston, Houston, TX

P2-10-19

Association between objective and perceived breast cancer risk with screening behaviors among racially/ethnically diverse women

Rhea N Shah, New York-Presbyterian/Columbia University Irving Medical Center, New York, NY

P2-10-20

Screening for breast cancer in women with extremely dense breasts: factors associated with uptake of MRI and ultrasonography

Alissa M Michel, Columbia University, New York, NY

P2-10-21

Long term outcomes of breast cancer diagnosis according to particiaption in population based screening

Gregory Bruce Mann, Royal Melbourne Hospital, Parkville, Australia

P2-10-22

Automation bias in breast ultrasound: The effect of using S-Detect on examiners’ decision in breast lesions

Christian Eichler, St. Franziskus-Hospital Münster, Münster, Germany

P2-10-23

Ultrasonographic assessment of the breast cancer growth rate in the interval between NACT and surgery

Mahmoud Al-Masri, King Hussein Cancer Center, Amman, Jordan

P2-10-24

Magnetic Resonance Imaging (MRI) supplemental breast screening: limited uptake of recommendations in women with increased breast density

Yanwan Dai, Duke University, Durham, NC

P2-10-25

Prediction of surgical margin in lobular breast cancer using multimodal electronic health records data

Emma Cepukenas, University of Wisconsin, Madison, Madison, WI

P2-10-26

Radiation dosimetry and delayed uptake study of the radiolabelled Affibody® molecule [<sup>18</sup>F]GEH121224 HER2 tracer in breast cancer patients, phase 1 HERPET-L and HERPET-D studies.

Laura Kenny, Imperial College London, London, United Kingdom

P2-10-27

Longitudinal Multimodal Imaging Biomarkers for Individualized High-Risk Breast Surveillance

Yutong Li, The University of Texas MD Anderson Cancer Center, Houston, TX

P2-10-28

Incidence and Predictors of Radiologic-Pathologic Tumor Size Discordance in Invasive Lobular Carcinoma

Wenhui Zhou, University of Wisconsin, Madison, Madison, WI

P2-10-29

Imaging response to CDK4/6 inhibition in hormone sensitive HER2 negative (HR+ HER2-) metastatic breast cancer patients with FDG-PET and D4-choline

Laura Kenny, Imperial College London, London, United Kingdom

P2-10-30

Optimizing Axillary Management in Early-Stage Breast Cancer with <sup>68</sup>Ga-FAPI PET/CT: A Path Toward Surgical De-escalation

Kejing Zhang, Xiangya Hospital, Central South University, Changsha, China

P2-11-01

Pretreatment MRI habitat signatures predict recurrence-free survival in triple negative breast cancer

Anum S. Kazerouni, University of Washington, Seattle, WA

P2-11-02

Closing the gap between breast cancer risk identification and prevention referral: Early findings from a technologist-led QI workflow

Yolcar Chamorro, Baptist Health Herbert Wertheim Cancer Institute, Miami, FL

P2-11-05

A potential new biomarker for enhanced molecular imaging of breast cancer

CHRISTINE CHAVANY, Milagen, Inc., Emeryville, CA

P2-11-06

Change in Background Parenchymal Enhancement on Serial Breast MRIs Among Women with Operable Breast Cancer Treated with Adjuvant Endocrine Therapy

Arshia Arora, Columbia University Irving Medical Center, New York, NY

P2-11-07

Clinical impact of breast MRI-detected internal mammary nodal involvement on multidisciplinary treatment recommendations in cN2-3 breast cancer

Mark Nguyen, University of Washington, Seattle, WA

P2-11-08

Performance of AI-alone reading as a triage tool in surveillance mammography for breast cancer patients: a longitudinal retrospective cohort study

Young-Jin Lee, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of

P2-11-09

Color-enhanced AI CADx for assessing response to neoadjuvant chemotherapy and hormonal therapy in breast cancer: a retrospective pilot study

Chirag Parghi, Jefferson Health-Lehigh Valley, Allentown, PA

P2-13-01

Diagnostic Performance and Efficiency of a Handheld Video-Rate Cellular-level Imaging System for Intraoperative Retroareolar Margin Assessment in Nipple-Sparing Breast Surgery

Chengdong Qin, zhejiang cancer hospital, hangzhou, China

P2-13-02

Impact of residual ductal carcinoma in situ on outcome in exceptional good responders with a pathologic complete response after neoadjuvant chemotherapy who are initially clinically node-positive breast cancer in the Neosenti-Turk Trials MF1802-03

Neslihan Cabioglu, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey

P2-13-04

Effects of Adjuvant Endocrine and Radiation Therapy on Breast Cancer Specific and Overall Survival in Patients with Node-Negative Hormone Positive Microinvasive Ductal Carcinoma in Situ

Gabrielle K Rajulu, UC San Diego Health, La Jolla, CA

P2-13-05

Clinical Utility of Multimodal MRI-US, CEUS, and US-US Fusion Imaging During Radiofrequency Ablation for Early-Stage Breast Cancer

TAKAFUMI NAGAYAMA, Kindai University, Osaka, Japan

P2-13-06

Beyond SOUND and INSEMA: a structured evidence review and clinical framework for axillary surgery omission in underrepresented subgroups

Paul TR Thiruchelvam, Imperial College, London, United Kingdom

P2-13-07

Residual ductal carcinoma in situ and axillary nodal disease after neoadjuvant chemotherapy: a subtype-specific analysis in human epidermal growth factor receptor 2-positive and triple-negative breast cancer

Chi Hoon Lee, Samsung Medical Center, Seoul, Korea, Republic of

P2-13-08

Preoperative GLP-1 receptor agonist use and postoperative outcomes following mastectomy according to reconstruction status

Monique John, Albany Medical College, Albany, NY

P2-13-09

When residual disease after neoadjuvant chemotherapy in breast cancer is detected exclusively by surgical axillary staging: Results from the prospective AXSANA/EUBREAST 03(R)/ AGO-B 53 study

Henning Schäffler, University Hospital Ulm, Ulm, Germany

P2-13-10

Glp-1 receptor agonists are associated with reduced wound complications in microsurgical breast reconstruction

Rachel N. Rohrich, University of Texas Southwestern, Dallas, TX

P2-13-11

Postoperative Radiotherapy Utilization and Survival Across Surgical Approaches in Stage I-III Breast Cancer: A NCDB Analysis

Magdalena Lombardi Plasilova, Weill Cornell Medicine, New York, NY

P2-13-12

Prognostic significance of quantifying lymphovascular invasion in cT1N0 breast cancer: implications for management in an era of de-escalation

Thomas Amburn, New York University Grossman School of Medicine, New York, NY

P2-13-13

Operative Time and 30-Day Complications in Immediate Implant-Based Breast Reconstruction: An NSQIP Analysis of Direct-to-Implant versus Tissue Expander Approaches

Gabriela Perez Alvarez, Florida International University, Miami, FL

P2-13-14

Implementation and Early Outcomes of Robotic Nipple-Sparing Mastectomy with Immediate Reconstruction-A Consecutive Single-Surgeon Experience from India

Jayanti Thumsi, HCG Hospital, Bengaluru, India

P2-13-15

Sentinel Lymph Node Biopsy Following Neoadjuvant Systemic therapy: A Sub-Study of the ROSCO Randomised Trial

Stuart A McIntosh, Queen's University Belfast, Belfast, United Kingdom

P2-13-16

Tumour Focality, Surgical Approach and Oncological Outcomes Following Neoadjuvant Chemotherapy in Breast Cancer

Eliana Kalakouti, Royal Marsden Hospital, London, United Kingdom

P2-13-17

Optimization of Axillary Strategies Based on AI Analysis: Indications and Safety of Selectively Omitting Rapid Diagnosis via Intraoperative Frozen Section Examination of Sentinel Lymph Nodes

Junichi Mase, Gifu Prefectural General Medical Center, Gifu City, Japan

P2-13-18

Factors Associated with Early vs Late Ipsilateral Recurrence After Breast Conserving Surgery

Matthew Sporn, NYU Langone, New York, NY

P2-13-19

Primary breast neuroendocrine carcinoma: clinicopathologic features and survival compared with invasive carcinoma with neuroendocrine differentiation

Risa Kiernan, Memorial Sloan Kettering Cancer Center, New York, NY

P2-13-20

Sentinel lymph node biopsy identifies residual nodal disease beyond targeted axillary biopsy in patients managed without axillary dissection after neoadjuvant chemotherapy

Yagmur Ozge Turac Kosem, University of Pittsburgh Medical Center- Maggee Womens Hospital, Pittsburgh, PA

P2-13-21

Identifying candidates for adjuvant CDK 4/6 inhibitor or chemotherapy after omission of sentinel lymph node biopsy for ER+HER2- early stage breast cancer

Stephen F. Sener, Los Angeles General Medical Center, Los Angeles, CA

P2-13-22

Efficacy of Intraoperative Ultrasonography and Magnetic Markers in Achieving Clear Surgical Margins in Oncoplastic Surgery Following Neoadjuvant Chemotherapy in Breast Cancer

Guldeniz Karadeniz Cakmak, Zonguldak Bulent Ecevit University The School of Medicine, Zonguldak, Turkey

P2-13-23

Contrast-enhanced ultrasound combined with methylene blue for sentinel lymph node biopsy after neoadjuvant chemotherapy in initially cN1 breast cancer: a multi-center prospective cohort study.

Duanyang Zhai, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

P2-13-24

Perioperative opioid exposure is associated with postoperative gut microbiome disruption in women undergoing breast surgery

Kristin Rojas, UT MD Anderson Cancer Center, Houston, TX

P2-13-25

Prophylactic LVA at Axillary Dissection Prevents breast Cancer Related Lymphoedema: Norman Scale QoL Outcomes India’s Largest Consecutive Series

Nishitha Prashanth, Aster international institute of oncology, Bengaluru, India

P2-13-26

Three-year Survival after Sentinel Lymph Node Biopsy versus Axillary Lymph Node Dissection in Patients with cT4N0-1 Breast Cancer after Neoadjuvant Systemic Therapy

Mavzuna Kurbanova, N.N. Blokhin Russian Cancer Research Cente, Moscow, Russian Federation

P2-13-27

Beyond Average Risk: Breast Atypia in Women with Prior Atypia or Breast Cancer

Molly Wilgucki, University of Rochester Wilmot Cancer Institute, Rochester, NY

P2-13-28

Incidental Pathological Findings Following Gender-Affirming Mastectomy: Implications for Breast Cancer Risk Assessment and Screening

Zainab Kiyam, MedStar Baltimore, Baltimore, MD

P2-13-29

Indocyanine Green as a Single Tracer for Sentinel Lymph Node Biopsy in Early Breast Cancer: Prospective UK Implementation Study of 300 Consecutive Patients

Alessio Vinci, Ninewells Hospital and Medical School, Dundee, United Kingdom

P2-14-01

Differential impact of breast cancer surgical procedures on postoperative daily life: a multicenter collaborative outcomes study in Japan.

Hirohito Seki, NHO Tokyo Medical Center, Tokyo, Japan

P2-14-02

The AWOgyn Breast Implant Registry: analysis of 10-years and 24,055 surgical procedures in Germany

Marc Antonius Maria Thill, Agaplesion Markus Krankenhaus, Frankfurt, Germany

P2-14-03

Oncological safety of deescalation of axillary surgery in clinically node-positive breast cancer with extraaxillary nodal extension showing a favorable response to neoadjuvant chemotherapy

Neslihan Cabioglu, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey

P2-14-04

Surgical Management and Outcomes in Young Women <40 years with Breast Cancer

Rahul Rangan, Cleveland Clinic Foundation, Cleveland, OH

P2-14-05

Surgical Patterns in Asian American Breast Cancer: Variation by Geographic and Ethnic Subgroup

Andrew Seto, Icahn School of Medicine at Mount Sinai, New York City, NY

P2-14-06

Accuracy of Post-Neoadjuvant Axillary Staging in HER2-Positive Breast Cancer and Its Impact on Eligibility for Adjuvant Trastuzumab Deruxtecan

Natalia Polidorio, Rede Americas Oncology, Brasília, Brazil

P2-14-07

Geographic Heterogeneity in Predictors of Contralateral Prophylactic Mastectomy Use in the United States

Michelle Ki, Montefiore Medical Center, Bronx, NY

P2-14-08

Prepectoral vs Submuscular Implant Based Reconstruction After Risk Reducing Nipple Sparing Mastectomy in Patients with Pathogenic Variants: A Multicenter Cohort Study

Francisco Pimentel Cavalcante, Hospital Geral de Fortaleza, Fortaleza, Brazil

P2-14-09

Nodal Upstaging Patterns in cN0 Early Breast Cancer: Differential Rates across Biological Subtypes in Upfront Surgery and Post‑Neoadjuvant Settings

Irina Kolyadina, V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation, Moscow, Russian Federation

P2-14-10

Clinicopathological Factors Associated with Residual Tumor in Additional Surgery for Close Margins After Breast-Conserving Surgery: A 495-Patient Retrospective Study

Yasuaki Uemoto, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan

P2-14-11

Development and Validation of a 4C/ID Model-Based Training and Competency Assessment System for Endoscopic and Robotic Scarless Breast Surgery: A Multicenter Cohort Study on Surgeon Skill Improvement and Patient Quality of Life

Yunjian Zhang, The First Affiliated Hospital of SUN YAT-SEN University, Guangzhou, China

P2-14-12

Intraoperative 5-aminolevulinic acid photodynamic diagnosis for margin assessment in breast cancer: a second prospective trial across unrestricted tumor sizes

Haruru Kotani, Aichi Cancer Center, Nagoya, Japan

P2-14-13

De-escalation of Nodal Surgery in Inflammatory Breast Cancer: Is this safe?

Laura Tunison, UTHSC-Nashville, Nasvhille, TN

P2-14-14

Perfact trial: a prospective case-control study to compare tissue perfusion between retractors and non-retractors during immediate breast reconstruction

Amit Agrawal, Cambridge University hospitals, Cambridge, United Kingdom

P2-14-15

Determinants of Mastectomy Decision-Making in a Contemporary Oncoplastic Breast Unit: A Two-Year Cohort Study

Mohammed Elmorsy, Hywel Dda University Health Board, Llanelli, United Kingdom

P2-14-16

Biosym: a feasibility randomised controlled trial comparing biological matrices with synthetic meshes in women undergoing one-stage implant-based breast reconstruction

Amit Goyal, Royal Derby Hospital, Derby, United Kingdom

P2-14-17

Trends and Predictors of Surgery in De-Novo Stage IV Breast Cancer: A National Cancer Database Analysis

Olga Kantor, Northwestern University, Chicago, IL

P2-14-18

Early Clinical Outcomes and Oncologic Safety of Paste-type Acellular Dermal Matrix in Patients Undergoing Breast Conserving Surgery: A Retrospective Single-Center Study

Hyoo Ran Lim, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of

P2-14-19

Axillary disease burden in index IMLN positive (cN3b) breast cancer patients treated with Neoadjuvant Systemic Therapy

Dileep Ramesh Hoysal, Tata Memorial Centre, Mumbai, India

P2-14-20

Implant-based breast reconstruction outcomes following perioperative pembrolizumab exposure: a propensity score-matched analysis

Stephanie Rice, UTSW, Dallas, TX

P2-14-21

Extending axillary de-escalation below age 70: a population-based analysis of women with favorable tumor biology

Claire Liu, University of British Columbia, Vancouver, BC, Canada

P2-14-22

Clinical Outcomes of a Novel Reverse Pocket Technique for TIVAP Implantation in Patients with Breast Cancer: A Propensity Score-Matched Study

Xinwei Liu, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

P2-14-23

Perioperative GLP-1 use and risk of breast cancer related lymphedema

Mary B Coomes, Rush University Medical Center, Chicago, IL

P2-14-24

Single-port robotic versus conventional open surgery for early breast cancer: a comparative study

Guangqian Shen, Beijing Chao-yang Hospital, Beijing, China

P2-14-25

Should LCIS be excised in Patients with Prior or Synchronous Breast Cancer?

Matthew Sporn, NYU Langone, New York, NY

P2-14-26

Metastatic tumor size and extranodal extension on axillary core needle biopsy predict axillary tumor burden and response to primary systemic therapy in breast cancer

Rikiya Nakamura, Chiba Cancer Center, Chiba, Japan

P2-14-27

Impact of Additional Deep Parenchymal Bupivacaine Infiltration on Postoperative Pain After Breast-Conserving Surgery

Zainab Kiyam, MedStar Baltimore, Baltimore, MD

P2-14-28

Are There Regional and Age-Related Disparities in the Utilization of Nipple-Sparing Mastectomy?

Mio Adachi, National Cancer Center Hospital East, Kashiwa-city, Japan

P2-14-29

Shallow whole genome sequencing for tailored treatment of ductal carcinoma in situ

Julie Le, UC San Diego Health, La Jolla, CA

P2-14-30

Nipple delay is associated with the absence of full-thickness nipple-areolar complex necrosis in high-risk nipple-sparing mastectomy

Koshi Matsui, University of Toyama, Toyama, Japan

P2-15-01

Surgical outcomes following neoadjuvant pembrolizumab for early-stage breast cancer: a systematic review and meta-analysis

Paul TR Thiruchelvam, Imperial College, London, United Kingdom

P2-15-02

Safety of periareolar-type Incisions in nipple-sparing mastectomy: nipple ischemia and early surgical outcomes in a Korean tertiary center

JAEWON CHOI, The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of

P2-15-03

Breast sarcoma: a rare malignant neoplasm. single-center case series (2010-2024) and literature review.

KAROLL TATIANA MEZA GARCIA, National institute of diseases neoplastic, LIMA, Peru

P2-15-04

Robotic Robotic Visualization of Breast Fascial Anatomy During Fascia-Guided Nipple-Sparing Mastectomy

HENG CAO, Capital Medical University Beijing Chao-Yang Hospital, Beijing, China

P2-15-05

Incomplete Mastectomies Give Rise to Local Breast Cancer Recurrence

Shyamin Mehra, Stanford University School of Medicine, Stanford, CA

P2-15-06

Tumour shape and the surgical pathway after neoadjuvant therapy: baseline MRI shape irregularity as a hypothesis-generating marker of mastectomy in unicentric breast cancer

Antonio Sampaio Soares, Instituto Português Oncologia Lisboa, Lisbon, Portugal

P2-15-07

From Course to Operating Room: Adoption of Endoscopic Nipple-Sparing Mastectomy Following Structured Training Among North American Breast Surgeons

Paula Escobar, Cleveland Clinic, Cleveland, OH

P2-15-08

Risk of local recurrence following skin- and nipple-sparing mastectomy according to breast cancer subtype

Chiara Tommasi, University Hospital of Parma, Parma, Italy

P2-15-09

Breast Cancer Subtype and Successful Axillary De-escalation Following Neoadjuvant Chemotherapy: A Single-Institution Retrospective Study

Cameron Kirkendoll, The University of Oklahoma Health Sciences Center, Oklahoma City, OK

P2-15-10

Interpreting and Stratifying Positive Frozen Results During Targeted Axillary Dissection After Neoadjuvant Therapy: Overtreatment or Appropriate Escalation?

Skylar Harbour, Albert Einstein College of Medicine, Bronx, NY

P2-15-11

Single-port endoscopic nipple-sparing mastectomy using the HandX articulating system: early clinical and patient-reported outcomes from the prospective ATHENA I study

Vasileios Kalles, Mediterraneo Hospital, Glyfada, Greece

P2-15-12

Omission of Sentinel Lymph Node Biopsy in Older Women (Age >70 Years) with Early-Stage, Hormone Receptor-Positive Breast Cancer: A Systematic Review of Oncologic and Functional Outcomes

Reem Nasraldeen, The Combined Research Foundation, Okemos, MI

P2-15-13

Outcomes following non-risk-reducing contralateral mastectomy for symmetry: A qualitative cohort study

David Westbroek, Dartford & Gravesham NHS Trust, Dartford, United Kingdom

P2-15-14

Experience Sharing of Endoscopy-Assisted Total Mastectomy with and without Immediate Breast Reconstruction

Zhang Hui, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China

P2-15-15

Navigational Targeted Lymphadenectomy in Early Breast Cancer with Nodal Status Conversion cN1→ycN0: First Results of a Russian Prospective Single‑Center Study

Irina Kolyadina, Russian Medical Academy of Continuing Professional Education, Ministry of Health of the Russian Federation, Moscow, Moscow, Russian Federation

P2-15-16

Upfront Surgical Management of Early-Stage Breast Cancer: A National Modified Delphi Consensus from the Brazilian Society of Surgical Oncology.

Leonardo de Sousa Santos, Brazilian Society of Surgical Oncology, Rio de Janeiro, Brazil

P2-15-17

Total mastectomy for elderly patients with fluid collection method without reconstruction by endoscopic breast surgery

Koji Yamashita, Nippon Medical School, Bunkyo-ku, Tokyo, Japan

P2-15-18

Selective Omission of Intraoperative Frozen Section Analysis During Targeted Axillary Dissection Following Neoadjuvant Therapy

Skylar Harbour, Albert Einstein College of Medicine, Bronx, NY

P2-15-19

Architecturally intact en bloc breast biopsy using a novel device: results from a prospective ex vivo study

Per Hellman, Uppsala University, Uppsala, Sweden

P2-15-20

A Multicenter Retrospective Study on Screening Patients Eligible for Exemption from Axillary Surgery Based on the Pathological Remission of the Breast after Neoadjuvant Therapy

Xingye Sheng, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

P2-15-21

Inframammary Fold Approach for Robot-Assisted Nipple-Sparing Mastectomy with Immediate Breast Reconstruction: An Initial Series of 109 Consecutive Cases

Hong-Kyu Kim, Seoul National University College of Medicine, Seoul, Korea, Republic of

P2-15-22

Single versus double surgeon approach for nipple-sparing mastectomy with implant-based reconstruction: a multicenter cohort study

Francisco Pimentel Cavalcante, Hospital Geral de Fortaleza, Fortaleza, Brazil

P2-15-23

Preoperative Imaging and Clinicopathologic Predictors of Re-excision Following Breast-Conserving Surgery

Michelle Ki, Montefiore Medical Center, Bronx, NY

P2-15-24

Residual Axillary Nodal Burden After Positive Sentinel Lymph Node Biopsy Following Neoadjuvant Chemotherapy

Soong June Bae, Gangnam Severacne Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of

P2-15-25

Minimal access NSM followed by HBOT for prevention of NAC ischemia and necrosis: a controlled clinical study

Peng Gao, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

P2-15-26

Single-port robot-assisted nipple-sparing mastectomy with immediate direct-to-implant reconstruction using a conventional inframammary fold approach: feasibility and early outcomes

Jeong hun Oh, Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of

P2-15-27

Effect of Modified Flap Fixation using sutures technique in total mastectomy on incidence of postoperative seroma formation

Shogo Nakano, Aichi Medical University, Nagakute-city, Japan

P2-15-29

Clinical Impact of Sentinel Lymph Node Biopsy on Adjuvant Treatment Decisions in Patients Meeting SOUND Trial Criteria

Maria Jesus J Pla-Farnos, Hospital Universitario de Bellvitge, Hopitalet de Llobregat-Barcelona, Spain

P2-15-30

Early Clinical Experience with Robot-Assisted Nipple Sparing Mastectomy Using the da Vinci System: A multidisciplinary Team-Based Implementation Strategy

Nami Yamashita, Cancer Institute Hospital of JFCR, Tokyo, Japan

P2-12-29

Postoperative complications, patient-reported outcomes, and satisfaction following endoscopic-assisted nipple-sparing mastectomy with immediate implant-based breast reconstruction: A single-center retrospective analysis of 105 cases

Hong Hu, Shenzhen People’s Hospital (The First Affiliated Hospital, Southern University of Science and Technology；The Second Clinical Medical College, Jinan University ), Shenzhen, China

P2-12-30

Neoadjuvant endocrine therapy increases wound complications but not flap failure following immediate autologous breast reconstruction.

Shiho Nagasawa, University of Toyama, Toyama, Japan

P2-11-16

Practice patterns for de-escalation of early-stage breast cancer treatment in a statewide consortium: Sentinel lymph node biopsy omission, partial breast radiation, and the combination of treatments over time

Michelle Tibbs, University of Michigan, Ann Arbor, MI

P2-11-17

India’S first centre to clinically implement ioert in breast-conserving surgery ioert boost + ebrt vs ebrt alone in breast-conserving surgery: oncological outcomes, quality of life, complications, cost analysis, and 3-year follow-up a prospective case-control study of 400 patients from india

Nishitha Prashanth, Aster international institute of oncology, Bengaluru, India

P2-11-18

Magnetic-controlled precision radiation therapy reduces skin dose without compromising target coverage in whole-breast irradiation: a treatment-planning study

Minji Koh, Kangwon National University Hospital, Chuncheon-si, Gangwon-do, Korea, Republic of

P2-11-19

Treatment Efficiency and Stability of Deep Inspiration Breath-Hold Moderately or Ultra Hypofractionated Radiotherapy in Breast Cancer

Shujun Zhang, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

P2-11-20

Impact of beam energy on skin dose and acute toxicity in prone hypofractionated whole breast irradiation with simultaneous integrated boost

Kylie Cox, University of California, Irvine, Irvine, CA

P2-11-21

Internal Mammary Lymph Node Boost in Advanced Breast Cancer: Quantification of Dosimetric Benefits of Proton Versus Photon Therapy and Early Toxicity Outcomes

Sarah R Rumley, University of Wahsington, Seattle, WA

P2-11-22

Fatigue trajectories during hypofractionated adjuvant breast radiotherapy: A prospective longitudinal study of the impact of prior systemic therapy

Efrat Gur, Beilinson hospital, Hod Hasharon, Israel

P2-11-23

Impact of Preoperative Breast MRI in patients undergoing Accelerated Partial Breast Irradiation

Camille Hardy Abeloos, NYU Langone Health, New York, NY

P2-11-24

Feasibility and safety of concurrent antibody drug conjugates with extracranial radiation therapy in the real-world setting

Gabris Ni, University of South Florida, Tampa, FL

P2-11-25

Fr-101 chest dressing improves skin hydration and radiation-related symptoms during breast cancer radiotherapy: interim analysis of a prospective trial

Chin-Nan Chu, China Medical University Hospital, Taichung, Taiwan

P2-11-26

Dosimetric Optimization and Aesthetic Preservation in Ultra-Accelerated Interstitial Partial Breast Irradiation: A Comparative Real-World Cohort Study

Adhar Amritt, National Cancer Institute-All India Institute of Medical Science, Jhajjar, India

P2-11-27

Does Nodal Pathologic Complete Response Justify Omission of Postmastectomy Radiotherapy? A Systematic Review and Meta-analysis

Marcelo Antonini, Hospital do Servidor Publico estadual, Sao Paulo, Brazil

P2-11-28

Clinically relevant radioresistance rewires cGAS-STING-STAT signaling and metastatic programs in breast cancer

Mei-Ren Pan, Kaohsiung Medical University, Kaohsiung City, Taiwan

P2-11-30

Uncertainty-aware decision modeling with partially observable markov decision processes for adjuvant radiation therapy in breast cancer

Prabdeep S Gill, Dartmouth College, Hanover, NH

P2-12-01

Cosmetic Outcomes Following FAST-Forward Whole-Breast Irradiation With Simultaneous Integrated Boost: A Single-Institution Analysis

Dana Elhadad, Davidoff Cancer Center, Petach Tikva, Israel

P2-12-02

Online Adaptive Stereotactic Partial Breast Irradiation (A-SPBI) improves target coverage in early stage breast cancer

Akshata Badrayani, UT Southwestern, Dallas, TX

P2-12-03

Radiation therapy-related toxicities potentially spared by omitting regional nodal irradiation in ypN0 breast cancer following neoadjuvant therapy

Madeline Kim, University of Rochester School of Medicine and Dentistry, Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY

P2-12-04

Clinical Outcomes of Autologous Microvascular Breast Reconstruction Following Proton-Mediated Internal Mammary Lymph Node Boost

Sarah R Rumley, University of Wahsington, Seattle, WA

P2-12-05

First demonstration of B-VMAT achieving superior low-dose sparing to 3D-CRT and significant reduction in cardiac event predictors over T-VMAT in breast radiotherapy

Xinzhuo Wang, Tianjin Fifth Central Hospital, Tianjin, China

P2-12-06

Dcis patients who have high-risk clinicopathologic factors are eligible for randomization of radiotherapy after breast conservation surgery in NRG CC-016 as they are often ds low risk by the 7-gene biosignature

Rachel Rabinovitch, UCHealth Radiation Oncology – Anschutz Medical Campus, Aurora, CO

P2-12-07

Boost Irradiation After Breast-Conserving Surgery in the Contemporary Treatment Era: A Multicenter Retrospective Cohort Study in Japan

Akimitsu Yamada, Yokohama City University Hospital, Yokohama, Japan

P2-12-08

Accelerated Partial Breast Irradiation in Patients with Early-Stage Breast Cancer with Prior Breast Augmentation: the University of Miami Experience

Justin T Dreyer, University of Miami, Miami, FL

P2-12-09

Late Pulmonary and Rib Toxicity and Cardiac Events After Five-Fraction Breast Radiotherapy for Early-Stage Breast Cancer

Lauren H Petersen, Emory University School of Medicine, Atlanta, GA

P2-12-10

Novel Workflow for Combining Prone Positioning with Deep Inspiration Breath Hold for Treatment of Early-Stage Breast Cancer

Pule Wang, City of Hope Comprehensive Cancer Center, Duarte, CA

P2-12-11

Three-year morbidity and patient-reported outcomes after axillary radiotherapy versus axillary lymph node dissection following neoadjuvant systemic therapy: results from the randomized phase iii adarnat trial (NCT04889924)

Maria Laplana-Torres, Hospital Clínic Barcelona, Barcelona, Spain

P2-12-12

Radiation delivery and quality review on the NRG Oncology/NSABP B-51/RTOG 1304 Phase III clinical trial evaluating regional nodal irradiation in responders to neoadjuvant chemotherapy

Julia R White, University of Kansas Medical Center Comprehensive Cancer Center, Kansas City, KS

P2-12-13

Clinical Outcomes Following Hypofractionated Versus Conventional Postmastectomy Radiation Therapy in Patients with Inflammatory Breast Cancer: A Single-Institution Experience

Raksha M Narasimhan, University of Miami Miller School of Medicine, Miami, FL

P2-12-14

Stereotactic Body Radiation Therapy Versus Conventional External Beam Radiation Therapy for Bone Metastases in De Novo Metastatic Breast Cancer: A National Cancer Database Analysis

Kaidi Wang, The Ohio State University Stefanie Spielman Comprehensive Breast Center, Columbus, OH

P2-12-15

Characterizing Cerebrospinal Fluid Dynamics After Craniospinal Irradiation for Leptomeningeal Metastasis

Ryan Mitchell, NYU Langone Health, New York, NY

P2-12-16

Prospective evaluation of implant-based breast reconstruction and postmastectomy radiotherapy using helical tomotherapy: Primary results from the MARTA trial

Carole Massabeau, Oncopole Claudius Regaud, TOULOUSE, France

P2-12-17

Atnm-400 a first-in-class targeted alpha therapy targeting a driver of tumor biology and treatment resistance demonstrates efficacy across therapy-resistant breast cancer subtypes

Adeela Kamal, Actinium Pharmaceuticals, Inc., New york, NY

P2-12-18

Quality of Life and Clinical Outcomes Following Intraoperative Radiation Therapy in Early-Stage Breast Cancer: A Prospective Registry Study

Aaron Shaykevich, SUNY Upstate Medical University, Syracuse, NY

P2-12-19

National Patterns of De-Escalation in Breast Cancer Management for Patients Aged ≥70 Years: A Multidisciplinary Survey Study

Kirti Sharma, Northwell Health, Forest Hills, NY

P2-12-20

Clinical Outcomes and Predictors of Intracranial Progression Following LINAC-Based SRS in Breast Cancer Brain Metastasis: A Single-Institution Experience

. Simran, All India Institute of Medical Sciences,New Delhi, New Delhi, India

P2-9-26

Mammary adipose tissue alters cancer cell adhesion and migration to drive obesity-linked breast cancer metastasis

Abby Jackson, University of Utah, Salt Lake City, UT

P2-9-27

A prospective, direct-to-patient study to evaluate clinical and molecular mechanisms of resistance to capivasertib in estrogen receptor-positive metastatic breast cancer

Jacqueline Jialin Tao, Mass General Brigham Cancer Institute, Boston, MA